RxDoctor Payments Data

Behnam Birgani, DO

Geriatric Medicine · Fort Lauderdale, FLNPI 1942381512

Payments from drug & device makers

$659in general payments, 2019–2025

Across 21 payments — averaging $31.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$391
  • Novartis$75
  • Exact Sciences$59
  • Boston Scientific$57
  • Lilly USA, LLC$30
  • Dexcom, Inc.$27
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK8$391
Novartis4$75
Exact Sciences3$59
Boston Scientific2$57
Lilly USA, LLC2$30
Dexcom, Inc.1$27
Amgen1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$659 in reported general payments places this provider in the 65th percentile of 305 geriatric medicine providers in Florida.

See all geriatric medicine providers in Florida

Medicare billing

Part B allowed, 2024
$284,799
Medicare patients
315
Services billed
2,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban328$145,422
TrulicityDulaglutide91$75,192
OzempicSemaglutide55$57,952
IngrezzaValbenazine Tosylate15$38,347
XareltoRivaroxaban53$32,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$24,711
TradjentaLinagliptin52$22,899
JardianceEmpagliflozin44$22,465
EntrestoSacubitril/Valsartan50$21,032
MounjaroTirzepatide14$17,463
Incruse ElliptaUmeclidinium Bromide46$17,413
LinzessLinaclotide14$12,971
FarxigaDapagliflozin Propanediol19$9,803
Combivent RespimatIpratropium/Albuterol Sulfate17$8,826
Breo ElliptaFluticasone/Vilanterol22$8,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$30$92,655105 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta$391$56,838114 claims
NovartisEntresto$75$21,03250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 305 geriatric medicine providers in Florida.

Other geriatric medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →